Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31408514 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2PTGESMAPK1EPHX2PDCD1 | |
| SCHEMBL31408356 | 0.89 | POLB (0.39) | LRRK2SMN1; SMN2MAPK1MLLT1 | |
| SCHEMBL31408509 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2PTGESMAPK1EPHX2PDCD1 | |
| SCHEMBL31408430 | 0.88 | MAPK1 (0.37) | SMN1; SMN2PTGESMAPK1EPHX2ALK | |
| SCHEMBL31408623 | 0.88 | SMN1; SMN2 (0.34) | SMN1; SMN2PTGESMAPK1EPHX2 | |
| SCHEMBL31408279 | 0.86 | SMN1; SMN2 (0.36) | LRRK2SMN1; SMN2PTGESMAPK1ALK | |
| SCHEMBL31408537 | 0.86 | SMN1; SMN2 (0.36) | LRRK2SMN1; SMN2PTGESMAPK1PDCD1 | |
| SCHEMBL31408312 | 0.86 | PTGES (0.37) | SMN1; SMN2PTGESPDCD1CD274DGAT1 | |
| SCHEMBL31408301 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2PTGESKCNH2 | |
| SCHEMBL31408575 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049604-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |